Vanda Pharmaceuticals Announces Phase III Study Results Showing Significant Reduction In GLP-1 Therapy-Associated Vomiting With NEREUS
NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomitingKey ResultsAny vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27% relative
Vanda made a medicine that helps reduce vomiting from a popular weight loss drug. When someone is thinking about this company, they might watch to see if doctors will use this new medicine.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.